Akari Therapeutics plc ADR (0.01 USD)

Day range

$7.64 – $8.45

Open

$7.64

Prev close

$8.23

Volume

25.92K

Market cap

$18.8M

Shares out

2.29M

P/E

—

P/S

—

P/B

1.01

P/FCF

—

ROE

-166.5%

ROA

-80.2%

Debt/Equity

0.04

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeOct 1, 2026

  On September 29, 2026, Akari Therapeutics, Plc entered into an amendment to its Chief Executive Officer Agreement... amended the CEO Agreement to provide for... “an increase in Mr. Gaslightwala's annual base salary from $475,000 to $625,000” and “an increase in Mr. Gaslightwala's target annual bonus opportunity from 50% of base salary to 55% of base salary.”

• Director departureJul 2, 2026

  At the Annual General Meeting, James Neal was not re-elected to the Board of Directors, having failed to receive the requisite shareholder approval. Accordingly, Mr. Neal's service as a director ended upon the conclusion of the Annual General Meeting.

• Private placementJun 26, 2026

  the Company agreed to sell and issue in a private placement (the "Offering") an aggregate of 1,470,588 unregistered American Depository Shares ("ADSs"), or prefunded warrants to purchase ADSs, each representing 80,000 of the Company's ordinary shares per ADS, together with Series H warrants, Series I warrants and Series J warrants to purchase an equivalent number of ADSs

• Private placementMay 22, 2026

  On May 20, 2026, Akari Therapeutics, Plc (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain investors, pursuant to which the Company agreed to sell and issue in a private placement (the "Offering") an aggregate of 1,470,588 unregistered American Depository Shares ("ADSs")... The securities to be issued to the purchasers under the Purchase Agreement were offered in reliance on an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and Rule 506 of Regulation D promulgated thereunder.

• Stock splitMar 17, 2026

  The Company announced that it plans to change the ratio of its American Depositary Shares ("ADSs") from one (1) ADS representing two thousand (2,000) Ordinary Share to one (1) ADS representing eighty thousand (80,000) Ordinary Shares. The Ratio Change will result in a one for forty reverse split of issued and outstanding ADSs, and it will be effective on or about March 31, 2026.

Days to cover

1.0

Short interest

14.53K

Avg volume

62.37K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
  positiveGlobeNewswire Inc.· Aug 4, 2026
• Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
  positiveGlobeNewswire Inc.· Jan 9, 2026
• Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
  positiveBenzinga· Nov 14, 2024
• Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
  GlobeNewswire Inc.· May 16, 2024
• Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
  GlobeNewswire Inc.· May 1, 2024